Klinische Neurodegeneration

Klinische Neurodegeneration - Ursachen, Früherkennung und Therapiestrategien

 

Die Forschungsgruppe "Klinische Neurodegeneration" befasst sich mit häufig vorkommenden neurodegenerativen Erkrankungen, v.a. der Parkinsonerkrankung und Demenzerkrankungen, die mit Bewegungsstörungen einhergehen. Schwerpunkte der Arbeitsgruppe liegen dabei auf der Identifikation von Markern, welche eine Früherkennung dieser Erkrankungen und Beurteilung des Krankheitsverlaufs erlauben. Hierbei werden u.a. genetische Varianten, Bewegungsparameter, eine Vielzahl nicht-motorischer Auffälligkeiten und kognitive Leistung erhoben und im Zusammenhang mit einem erhöhten Erkrankungsrisiko und einem veränderten Krankheitsverlauf erforscht. Anhand von etablierten Markern zur frühen, sicheren Diagnose und zur Vorhersage des Krankheitsverlaufs könnten Patienten und Risikogruppen identifiziert werden, welche von einer nervenzellschützenden Therapie profitieren. Mit dem Ziel zukünftig eine Modulation des Verlaufs und auch nervenzellschützende Therapien ermöglichen zu können, werden in der AG Klinische Neurodegeneration große, prospektive, longitudinale Kohortenstudien mit Patienten und Gesunden mit einem erhöhten Risiko für Parkinson und Demenzerkrankungen durchgeführt (siehe: Laufende Studien). Im Rahmen dieser groß angelegten Studien, sowie bei weiteren nationalen und internationalen Forschungsprojekten, arbeitet die Arbeitsgruppe eng mit zahlreichen Kooperationspartnern zusammen.

 

 

Forschungsprojekte
Mitarbeiter
Publikationen
Ambulanz

Parkinsonerkrankung

 

Um bessere Kenntnisse über den Verlauf der Parkinsonerkrankung zu erhalten und die Ursachen und Entstehung besser verstehen zu können, untersucht die AG Klinische Neurodegeneration im Rahmen nationaler und internationaler Kooperationen in großen, prospektiven, longitudinalen Kohortenstudien Patienten sowie Personen mit einem erhöhten Erkrankungsrisiko, um diagnostische und Verlaufs-Marker zu ermitteln und damit zu einem besseren Verständnis der zugrundeliegenden neurodegenerativen Prozesse beizutragen. Mit der Zielsetzung, bestehende Therapiestrategien für alle Stadien der Parkinsonerkrankung weiter zu verbessern, führt die Gruppe Klinische Neurodegeneration außerdem eine Vielzahl von mono- und multizentrischen Studien der Phase II – IV durch.

Früherkennung

 

Neurodegenerative Erkrankungen wie die Parkinsonerkrankung oder auch Demenz-Erkrankungen treten nicht plötzlich auf. Vor den ersten sichtbaren Symptomen ist bereits eine große Anzahl von Nervenzellen über Jahre zugrunde gegangen. Ursache und Art dieser frühen Schädigung sind bis heute wenig verstanden. Verschiedene Untersuchungen deuten jedoch darauf hin, dass ältere Menschen mit bestimmten Symptomen möglicherweise ein erhöhtes Risiko haben, an einem Parkinson-Syndrom oder einer Demenz zu erkranken. Zu diesen Symptomen gehören:

  • Auffälligkeiten im Ultraschall des Gehirns
  • Störung der Geruchswahrnehmung
  • REM-Schlafstörung
  • Depressionen
  • Verminderte Mitbewegung einer Körperseite bei starker körperlicher Belastung
  • Auffälligkeiten des autonomen Nervensystems, wie Verstopfung

Das bedeutet nicht, dass alle Menschen mit diesen Symptomen an einem Parkinson-Syndrom oder Demenz erkranken. Vielmehr werden die meisten Menschen mit den oben genannten Störungen nie von einer der beiden Erkrankungen betroffen. Dennoch können diese Symptome (sie werden auch klinische und bildgebende Marker genannt) auf eine Frühphase der beiden Erkrankungen hindeuten und somit wichtige Hinweise für den Verlauf bis zur Entwicklung eines Parkinson-Syndroms oder einer Alzheimer-Demenz geben. Diese wichtigen Daten werden im Rahmen von Früherkennungsstudien, wie z.B. der TREND-Studie (siehe: Laufende Studien / Früherkennung), erhoben und erforscht.

Genetische Ursachen der Parkinsonerkrankung

 

Die genauen Ursachen der Parkinsonerkrankung  sind bisher nicht gut verstanden. Es gibt jedoch zunehmend Hinweise, dass auch genetische Faktoren zur Entwicklung der Parkinsonerkrankung beitragen, sowohl bei Patienten mit mehreren Betroffenen in einer Familie, wie auch bei denen, die keinen Verwandten mit Parkinson haben (weiterführende Informationen). 

Trankranielle Sonographie (TCS)

 

Diese von Prof. Daniela Berg und Mitarbeitern maßgeblich entwickelte Methode wird sowohl in den Untersuchungen ambulanter und stationärer Patienten zur Erhärtung und Differentialdiagnose von Krankheitsbildern eingesetzt, wie auch in Studien untersucht, um die Bedeutung früher Veränderungen (z.B. der Substantia Nigra Hyperechogenität) als Risikomarker zu evaluieren. Regelmäßige internationale TCS-Kurse werden zur Ausbildung angeboten.

Standardisierung quantitativer Untersuchungen

 

Ein weiterer Schwerpunkt der Gruppe ist die Kooperation mit der AG Funktionelle Neurogeriatrie von Prof. Walter Maetzler zur Standardisierung quantitativer Untersuchungen einschließlich subtiler Motorik-Defizite wie z.B. Gangstörungen durch Verwendung eines Accelerometer-basierten Messsystems, der Feinmotorik sowie autonomer Störungen mittels spezieller Apparaturen. Eine Zuhilfenahme dieser Techniken wird neue Einblicke in die Pathophysiologie sowie den Verlauf von Krankheitsbildern in klinisch auffälligen wie auch in symptomfreien Stadien neurodegenerativer Erkrankungen erlauben.

Hertie Biobank

 

In Zusammenarbeit mit Prof. Thomas Gasser und Prof. Walter Maetzler ist die AG Klinische Neurodegeneration außerdem maßgeblich an der Entwicklung und Instandhaltung der Hertie Biobank, Leiter Prof. Walter Maetzler, beteiligt. Diese Biobank ist derzeit Grundlage für viele nationale und internationale Kooperationen und unterstützt eine erfolgreiche Forschung im Bereich der Parkinsonerkrankung und anderer neurodegenerativer Erkrankungen. 

Subgruppen der Parkinsonerkrankungen und andere Parkinsonsyndrome

 

Um der Forderung nach einer frühen, individuellen und besseren Therapie Rechnung tragen zu können, liegt ein weiterer Schwerpunkt der Gruppe in der Identifizierung von Parkinson-Patienten mit einem potentiell erhöhten Risiko, an Demenz zu erkranken und eine klarere Klassifizierung von Demenzen bei der Lewy Body Erkrankungen zu entwickeln. Außerdem wird intensiv an der Klassifizierung der Supranukleären Blickparese (PSP) gearbeitet, u.a. in Kooperation mit der AG atypische Parkinsonsyndrome der DPG (Deutsche Parkinsongesellschaft). Klinische, biochemische und bildgebende Parameter werden eingesetzt, um ein besseres Verständnis der PSP Subgruppen und zukünftige therapeutische Interventionen zu erhalten.

Restless-Legs-Syndrome Das Restless-Legs-Syndrome (RLS) ist eine sensomotorische Erkrankung von der etwa 10% der Deutschen Bevölkerung betroffen sind. Medikamentöse und Nicht-medikamentöse Beobachtungsstudien werden durchgeführt, um die Symptomatik der Betroffenen zu verbessern und einen möglichst beschwerdefreien Alltag zu gewährleisten.

 
Name
Arbeitsgruppe
Telefon
E-Mail
 Maren Albers
Maren Albers
Clinical Neurodegeneration
07071 29-85711 
Dr. Anja Apel
Dr. Anja Apel
Clinical Neurodegeneration
87598 
Prof. Dr. Daniela Berg
Prof. Dr. Daniela Berg Research Group Leader
Clinical Neurodegeneration
07071 29-83119 
M.Sc. Dominik Blum
M.Sc. Dominik Blum PhD Student
Clinical Neurodegeneration
07071 29-85137 
Dr. Kathrin Brockmann
Dr. Kathrin Brockmann Physician
Clinical Neurodegeneration
 
 Christian Deuschle
Christian Deuschle
Clinical Neurodegeneration
07071 29-82041 
Dr. Bettina Faust
Dr. Bettina Faust
Clinical Neurodegeneration
07071 29-87637 
 Katharina Gauss
Katharina Gauss Study Nurse
Clinical Neurodegeneration
07071 29-83272 
Dr. Susanne Gräber-Sultan
Dr. Susanne Gräber-Sultan
Clinical Neurodegeneration
07071 29-80424 
 Christine Haaga
Christine Haaga
Clinical Neurodegeneration
07071 29-85653 
Dr. Sebastian Heinzel
Dr. Sebastian Heinzel Biologist
Clinical Neurodegeneration
07071 29-87604 
 Heiderose Heiss
Heiderose Heiss
Clinical Neurodegeneration
 
Dr. Stefanie Lerche
Dr. Stefanie Lerche Biologist
Clinical Neurodegeneration
07071 29-80171 
Dr. Inga Liepelt-Scarfone
Dr. Inga Liepelt-Scarfone
Clinical Neurodegeneration
07071 29-80424 
 Corina Maetzler
Corina Maetzler
Functional Neurogeriatrics
07071 29-81969 
 Katja Michaelis
Katja Michaelis Study Assistant
Clinical Genetics of Paroxysmal Neurological Diseases
07071 29-80446 
 Andrea Pilotto
Andrea Pilotto
Clinical Neurodegeneration
 
 Ina Posner
Ina Posner Nurse
Clinical Neurodegeneration
 
 Benjamin Roeben
Benjamin Roeben
Clinical Neurodegeneration
07071 29-80438 
 Nicole Runge
Nicole Runge Study Nurse
Clinical Neurodegeneration
07071 29-85660 
 Eva Schaeffer
Eva Schaeffer
Clinical Neurodegeneration
 
 Claudia Schulte
Claudia Schulte
Clinical Neurodegeneration
07071 29-82041 
 Ulrike Sünkel
Ulrike Sünkel
Clinical Neurodegeneration
07071 29-85947 
 Zuzanna Tkaczynska
Zuzanna Tkaczynska
Clinical Neurodegeneration
07071 29-85790 
 Isabel Wurster
Isabel Wurster Physician
Clinical Neurodegeneration
07071 29-80171 
 Rezzak Yilmaz
Rezzak Yilmaz
Clinical Neurodegeneration
07071 29-87604 
Dr. Anna-Katharina von Thaler
Dr. Anna-Katharina von Thaler
Clinical Neurodegeneration
07071 29-80172 

Publikationen seit 2008

 

2014

 

Berg, D., Postuma, R.B., Bloem, B., Chan, P., Dubois, B., Gasser, T., Goetz, C.G., Halliday, G.M., Hardy, J., Lang, A.E., Litvan, I., Marek, K., Obeso, J., Oertel, W., Olanow, C.W., Poewe, W., Stern, M., and Deuschl, G. (2014). Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. Mov Disord 29, 454-462.

Bras, J., Guerreiro, R., Darwent, L., Parkkinen, L., Ansorge, O., Escott-Price, V., Hernandez, D.G., Nalls, M.A., Clark, L.N., Honig, L.S., Marder, K., Van Der Flier, W.M., Lemstra, A., Scheltens, P., Rogaeva, E., St George-Hyslop, P., Londos, E., Zetterberg, H., Ortega-Cubero, S., Pastor, P., Ferman, T.J., Graff-Radford, N.R., Ross, O.A., Barber, I., Braae, A., Brown, K., Morgan, K., Maetzler, W., Berg, D., Troakes, C., Al-Sarraj, S., Lashley, T., Compta, Y., Revesz, T., Lees, A., Cairns, N., Halliday, G.M., Mann, D., Pickering-Brown, S., Dickson, D.W., Singleton, A., and Hardy, J. (2014). Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. Hum Mol Genet.

Brockmann, K., and Berg, D. (2014). The significance of GBA for Parkinson's disease. J Inherit Metab Dis 37, 643-648.

Gaenslen, A., Wurster, I., Brockmann, K., Huber, H., Godau, J., Faust, B., Lerche, S., Eschweiler, G.W., Maetzler, W., and Berg, D. (2014). Prodromal features for Parkinson's disease--baseline data from the TREND study. Eur J Neurol 21, 766-772.

Heinzel, S., Liepelt-Scarfone, I., Roeben, B., Nasi-Kordhishti, I., Suenkel, U., Wurster, I., Brockmann, K., Fritsche, A., Niebler, R., Metzger, F.G., Eschweiler, G.W., Fallgatter, A.J., Maetzler, W., and Berg, D. (2014). A neurodegenerative vascular burden index and the impact on cognition. Front. Aging Neurosci., doi: 10.3389/fnagi.2014.00161

Lerche, S., Hobert, M., Brockmann, K., Wurster, I., Gaenslen, A., Hasmann, S., Eschweiler, G.W., Maetzler, W., and Berg, D. (2014a). Mild parkinsonian signs in the elderly--is there an association with PD? Crossectional findings in 992 individuals. PLoS One 9, e92878.

Lerche, S., Seppi, K., Behnke, S., Liepelt-Scarfone, I., Godau, J., Mahlknecht, P., Gaenslen, A., Brockmann, K., Srulijes, K., Huber, H., Wurster, I., Stockner, H., Kiechl, S., Willeit, J., Gasperi, A., Fassbender, K., Poewe, W., and Berg, D. (2014b). Risk factors and prodromal markers and the development of Parkinson's disease. J Neurol 261, 180-187.

Louter, M., Maetzler, W., Prinzen, J., Van Lummel, R.C., Hobert, M., Arends, J.B., Bloem, B.R., Streffer, J., Berg, D., Overeem, S., and Liepelt-Scarfone, I. (2014). Accelerometer-based quantitative analysis of axial nocturnal movements differentiates patients with Parkinson's disease, but not high-risk individuals, from controls. J Neurol Neurosurg Psychiatry.

Maetzler, W., Apel, A., Langkamp, M., Deuschle, C., Dilger, S.S., Stirnkorb, J.G., Schulte, C., Schleicher, E., Gasser, T., and Berg, D. (2014). Comparable autoantibody serum levels against amyloid- and inflammation-associated proteins in Parkinson's disease patients and controls. PLoS One 9, e88604.

Schondorf, D.C., Aureli, M., Mcallister, F.E., Hindley, C.J., Mayer, F., Schmid, B., Sardi, S.P., Valsecchi, M., Hoffmann, S., Schwarz, L.K., Hedrich, U., Berg, D., Shihabuddin, L.S., Hu, J., Pruszak, J., Gygi, S.P., Sonnino, S., Gasser, T., and Deleidi, M. (2014). iPSC-derived neurons from GBA1-associated Parkinson's disease patients show autophagic defects and impaired calcium homeostasis. Nat Commun 5, 4028.

Todd, G., Haberfield, M., Faulkner, P.L., Rae, C., Hayes, M., Wilcox, R.A., Taylor, J.L., Gandevia, S.C., Godau, J., Berg, D., Piguet, O., and Double, K.L. (2014). Hand function is impaired in healthy older adults at risk of Parkinson's disease. J Neural Transm.

Wurster, I., Abaza, A., Brockmann, K., Liepelt-Scarfone, I., and Berg, D. (2014). Parkinson's disease with and without preceding essential tremor-similar phenotypes: a pilot study. J Neurol 261, 884-888. 

2013

 

Appenzeller, S., Schulte, C., Thier, S., Hopfner, F., Pendziwiat, M., Papengut, F., Klein, C., Hagenah, J., Kasten, M., Srulijes, K., Berg, D., Gasser, T., Singleton, A., Deuschl, G., and Kuhlenbaumer, G. (2013). No association between polymorphisms in the glutamate transporter SLC1A2 and Parkinson's disease. Mov Disord 28, 1305-1306.

Berardelli, A., Wenning, G.K., Antonini, A., Berg, D., Bloem, B.R., Bonifati, V., Brooks, D., Burn, D.J., Colosimo, C., Fanciulli, A., Ferreira, J., Gasser, T., Grandas, F., Kanovsky, P., Kostic, V., Kulisevsky, J., Oertel, W., Poewe, W., Reese, J.P., Relja, M., Ruzicka, E., Schrag, A., Seppi, K., Taba, P., and Vidailhet, M. (2013). EFNS/MDS-ES/ENS [corrected] recommendations for the diagnosis of Parkinson's disease. Eur J Neurol 20, 16-34.

Berg, D., and Bandmann, O. (2013). Biomarkers for PD: How can we approach complexity? Neurology 80, 608-609.

Berg, D., Behnke, S., Seppi, K., Godau, J., Lerche, S., Mahlknecht, P., Liepelt-Scarfone, I., Pausch, C., Schneider, N., Gaenslen, A., Brockmann, K., Srulijes, K., Huber, H., Wurster, I., Stockner, H., Kiechl, S., Willeit, J., Gasperi, A., Fassbender, K., Gasser, T., and Poewe, W. (2013a). Enlarged hyperechogenic substantia nigra as a risk marker for Parkinson's disease. Mov Disord 28, 216-219.

Berg, D., Godau, J., Seppi, K., Behnke, S., Liepelt-Scarfone, I., Lerche, S., Stockner, H., Gaenslen, A., Mahlknecht, P., Huber, H., Srulijes, K., Klenk, J., Fassbender, K., Maetzler, W., Poewe, W., and Group, P.S. (2013b). The PRIPS study: screening battery for subjects at risk for Parkinson's disease. Eur J Neurol 20, 102-108.

Berg, D., Lang, A.E., Postuma, R.B., Maetzler, W., Deuschl, G., Gasser, T., Siderowf, A., Schapira, A.H., Oertel, W., Obeso, J.A., Olanow, C.W., Poewe, W., and Stern, M. (2013c). Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities. Lancet Neurol 12, 514-524.

Bottcher, T., Rolfs, A., Meyer, B., Grossmann, A., Berg, D., Kropp, P., Benecke, R., and Walter, U. (2013). Clinical, genetic, and brain sonographic features related to Parkinson's disease in Gaucher disease. J Neurol 260, 2523-2531.

Brendel, B., Ackermann, H., Berg, D., Lindig, T., Scholderle, T., Schols, L., Synofzik, M., and Ziegler, W. (2013). Friedreich ataxia: dysarthria profile and clinical data. Cerebellum 12, 475-484.

Brockmann, K., Schulte, C., Hauser, A.K., Lichtner, P., Huber, H., Maetzler, W., Berg, D., and Gasser, T. (2013). SNCA: major genetic modifier of age at onset of Parkinson's disease. Mov Disord 28, 1217-1221.

Christ, J.B., Fruhmann Berger, M., Riedl, E., Prakash, D., Csoti, I., Molt, W., Graber, S., Brockmann, K., Berg, D., and Liepelt-Scarfone, I. (2013). How precise are activities of daily living scales for the diagnosis of Parkinson's disease dementia? A pilot study. Parkinsonism Relat Disord 19, 371-374.

Fischer, M.D., Synofzik, M., Kernstock, C., Dietzsch, J., Heidlauf, R., Schicks, J., Srulijes, K., Wiethoff, S., Menn, O., Berg, D., Schols, L., and Schiefer, U. (2013). Decreased retinal sensitivity and loss of retinal nerve fibers in multiple system atrophy. Graefes Arch Clin Exp Ophthalmol 251, 235-241.

Funke, C., Schneider, S.A., Berg, D., and Kell, D.B. (2013). Genetics and iron in the systems biology of Parkinson's disease and some related disorders. Neurochem Int 62, 637-652.

Groger, A., Bender, B., Wurster, I., Chadzynski, G.L., Klose, U., and Berg, D. (2013). Differentiation between idiopathic and atypical parkinsonian syndromes using three-dimensional magnetic resonance spectroscopic imaging. J Neurol Neurosurg Psychiatry 84, 644-649.

Heinzel, S., Metzger, F.G., Ehlis, A.C., Korell, R., Alboji, A., Haeussinger, F.B., Hagen, K., Maetzler, W., Eschweiler, G.W., Berg, D., Fallgatter, A.J., and Consortium, T.S. (2013). Aging-related cortical reorganization of verbal fluency processing: a functional near-infrared spectroscopy study. Neurobiol Aging 34, 439-450.

Huttenbrink, K.B., Hummel, T., Berg, D., Gasser, T., and Hahner, A. (2013). Olfactory dysfunction: common in later life and early warning of neurodegenerative disease. Dtsch Arztebl Int 110, 1-7, e1.

Laske, C., Schmohl, M., Leyhe, T., Stransky, E., Maetzler, W., Berg, D., Fallgatter, A.J., Joos, T., and Dietzsch, J. (2013). Immune profiling in blood identifies sTNF-R1 performing comparably well as biomarker panels for classification of Alzheimer's disease patients. J Alzheimers Dis 34, 367-375.

Liepelt-Scarfone, I., Fruhmann Berger, M., Prakash, D., Csoti, I., Graber, S., Maetzler, W., and Berg, D. (2013a). Clinical characteristics with an impact on ADL functions of PD patients with cognitive impairment indicative of dementia. PLoS One 8, e82902.

Liepelt-Scarfone, I., Gauss, K., Maetzler, W., Muller, K., Bormann, C., Fruhmann Berger, M., Timmers, M., Streffer, J., and Berg, D. (2013b). Evaluation of progression markers in the premotor phase of Parkinson's disease: the progression markers in the premotor phase study. Neuroepidemiology 41, 174-182.

Liscic, R.M., Srulijes, K., Groger, A., Maetzler, W., and Berg, D. (2013). Differentiation of progressive supranuclear palsy: clinical, imaging and laboratory tools. Acta Neurol Scand 127, 362-370.

Mielke, M.M., Maetzler, W., Haughey, N.J., Bandaru, V.V., Savica, R., Deuschle, C., Gasser, T., Hauser, A.K., Graber-Sultan, S., Schleicher, E., Berg, D., and Liepelt-Scarfone, I. (2013). Plasma ceramide and glucosylceramide metabolism is altered in sporadic Parkinson's disease and associated with cognitive impairment: a pilot study. PLoS One 8, e73094.

Nalls, M.A., Duran, R., Lopez, G., Kurzawa-Akanbi, M., Mckeith, I.G., Chinnery, P.F., Morris, C.M., Theuns, J., Crosiers, D., Cras, P., Engelborghs, S., De Deyn, P.P., Van Broeckhoven, C., Mann, D.M., Snowden, J., Pickering-Brown, S., Halliwell, N., Davidson, Y., Gibbons, L., Harris, J., Sheerin, U.M., Bras, J., Hardy, J., Clark, L., Marder, K., Honig, L.S., Berg, D., Maetzler, W., Brockmann, K., Gasser, T., Novellino, F., Quattrone, A., Annesi, G., De Marco, E.V., Rogaeva, E., Masellis, M., Black, S.E., Bilbao, J.M., Foroud, T., Ghetti, B., Nichols, W.C., Pankratz, N., Halliday, G., Lesage, S., Klebe, S., Durr, A., Duyckaerts, C., Brice, A., Giasson, B.I., Trojanowski, J.Q., Hurtig, H.I., Tayebi, N., Landazabal, C., Knight, M.A., Keller, M., Singleton, A.B., Wolfsberg, T.G., and Sidransky, E. (2013). A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. JAMA Neurol 70, 727-735.

Reinhardt, P., Schmid, B., Burbulla, L.F., Schondorf, D.C., Wagner, L., Glatza, M., Hoing, S., Hargus, G., Heck, S.A., Dhingra, A., Wu, G., Muller, S., Brockmann, K., Kluba, T., Maisel, M., Kruger, R., Berg, D., Tsytsyura, Y., Thiel, C.S., Psathaki, O.E., Klingauf, J., Kuhlmann, T., Klewin, M., Muller, H., Gasser, T., Scholer, H.R., and Sterneckert, J. (2013). Genetic correction of a LRRK2 mutation in human iPSCs links parkinsonian neurodegeneration to ERK-dependent changes in gene expression. Cell Stem Cell 12, 354-367.

Schroeder, U., Behnke, S., Buchholz, H.G., Fassbender, K., Schreckenberger, M., and Berg, D. (2013). Substantia nigra hyperechogenicity in healthy controls: a [(1)(8)Fluoro] Dopa-PET follow-up study. J Neurol 260, 1907-1911.

Todd, G., Noyes, C., Flavel, S.C., Della Vedova, C.B., Spyropoulos, P., Chatterton, B., Berg, D., and White, J.M. (2013). Illicit stimulant use is associated with abnormal substantia nigra morphology in humans. PLoS One 8, e56438.

2012

 

Appenzeller, S., Thier, S., Papengut, F., Klein, C., Hagenah, J., Kasten, M., Berg, D., Srulijes, K., Gasser, T., Schreiber, S., Deuschl, G., and Kuhlenbaumer, G. (2012). No association between NOD2 variants and Parkinson's disease. Mov Disord 27, 1191-1192.

Berg, D. (2012). Is pre-motor diagnosis possible? The European experience. Parkinsonism Relat Disord 18 Suppl 1, S195-198.

Berg, D., Marek, K., Ross, G.W., and Poewe, W. (2012). Defining at-risk populations for Parkinson's disease: lessons from ongoing studies. Mov Disord 27, 656-665.

Berg, D., and Poewe, W. (2012). Can we define "pre-motor" Parkinson's disease? Mov Disord 27, 595-596.

Brockmann, K., Hilker, R., Pilatus, U., Baudrexel, S., Srulijes, K., Magerkurth, J., Hauser, A.K., Schulte, C., Csoti, I., Merten, C.D., Gasser, T., Berg, D., and Hattingen, E. (2012). GBA-associated PD. Neurodegeneration, altered membrane metabolism, and lack of energy failure. Neurology 79, 213-220.

Gerlach, M., Maetzler, W., Broich, K., Hampel, H., Rems, L., Reum, T., Riederer, P., Stoffler, A., Streffer, J., and Berg, D. (2012). Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeutics. J Neural Transm 119, 39-52.

Gispert, S., Kurz, A., Waibel, S., Bauer, P., Liepelt, I., Geisen, C., Gitler, A.D., Becker, T., Weber, M., Berg, D., Andersen, P.M., Kruger, R., Riess, O., Ludolph, A.C., and Auburger, G. (2012). The modulation of Amyotrophic Lateral Sclerosis risk by ataxin-2 intermediate polyglutamine expansions is a specific effect. Neurobiol Dis 45, 356-361.

Groger, A., and Berg, D. (2012). Does structural neuroimaging reveal a disturbance of iron metabolism in Parkinson's disease? Implications from MRI and TCS studies. J Neural Transm 119, 1523-1528.

Liepelt-Scarfone, I., Graber, S., Fruhmann Berger, M., Feseker, A., Baysal, G., Csoti, I., Godau, J., Gaenslen, A., Huber, H., Srulijes, K., Brockmann, K., and Berg, D. (2012). Cognitive profiles in Parkinson's disease and their relation to dementia: a data-driven approach. Int J Alzheimers Dis 2012, 910757.

Lill, C.M., Roehr, J.T., Mcqueen, M.B., Kavvoura, F.K., Bagade, S., Schjeide, B.M., Schjeide, L.M., Meissner, E., Zauft, U., Allen, N.C., Liu, T., Schilling, M., Anderson, K.J., Beecham, G., Berg, D., Biernacka, J.M., Brice, A., Destefano, A.L., Do, C.B., Eriksson, N., Factor, S.A., Farrer, M.J., Foroud, T., Gasser, T., Hamza, T., Hardy, J.A., Heutink, P., Hill-Burns, E.M., Klein, C., Latourelle, J.C., Maraganore, D.M., Martin, E.R., Martinez, M., Myers, R.H., Nalls, M.A., Pankratz, N., Payami, H., Satake, W., Scott, W.K., Sharma, M., Singleton, A.B., Stefansson, K., Toda, T., Tung, J.Y., Vance, J., Wood, N.W., Zabetian, C.P., Andme Genetic Epidemiology of Parkinson's Disease, C., International Parkinson's Disease Genomics, C., Parkinson's Disease, G.C., Wellcome Trust Case Control, C., Young, P., Tanzi, R.E., Khoury, M.J., Zipp, F., Lehrach, H., Ioannidis, J.P., and Bertram, L. (2012). Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: The PDGene database. PLoS Genet 8, e1002548.

Liu, C., Roder, C., Schulte, C., Kasuya, H., Akagawa, H., Nishizawa, T., Yoneyama, T., Okada, Y., Khan, N., Tatagiba, M., Berg, D., and Krischek, B. (2012). Analysis of TGFB1 in European and Japanese Moyamoya disease patients. Eur J Med Genet 55, 531-534.

Maetzler, W., Langkamp, M., Lerche, S., Godau, J., Brockmann, K., Gaenslen, A., Huber, H., Wurster, I., Niebler, R., Eschweiler, G.W., and Berg, D. (2012a). Lowered serum amyloid-beta1-42 autoantibodies in individuals with lifetime depression. J Alzheimers Dis 32, 95-100.

Maetzler, W., Mancini, M., Liepelt-Scarfone, I., Muller, K., Becker, C., Van Lummel, R.C., Ainsworth, E., Hobert, M., Streffer, J., Berg, D., and Chiari, L. (2012b). Impaired trunk stability in individuals at high risk for Parkinson's disease. PLoS One 7, e32240.

Maetzler, W., Tian, Y., Baur, S.M., Gauger, T., Odoj, B., Schmid, B., Schulte, C., Deuschle, C., Heck, S., Apel, A., Melms, A., Gasser, T., and Berg, D. (2012c). Serum and cerebrospinal fluid levels of transthyretin in Lewy body disorders with and without dementia. PLoS One 7, e48042.

Sathe, K., Maetzler, W., Lang, J.D., Mounsey, R.B., Fleckenstein, C., Martin, H.L., Schulte, C., Mustafa, S., Synofzik, M., Vukovic, Z., Itohara, S., Berg, D., and Teismann, P. (2012). S100B is increased in Parkinson's disease and ablation protects against MPTP-induced toxicity through the RAGE and TNF-alpha pathway. Brain 135, 3336-3347.

Saur, R., Maier, C., Milian, M., Riedel, E., Berg, D., Liepelt-Scarfone, I., and Leyhe, T. (2012). Clock test deficits related to the global cognitive state in Alzheimer's and Parkinson's disease. Dement Geriatr Cogn Disord 33, 59-72.

Schmid, S.P., Schleicher, E.D., Cegan, A., Deuschle, C., Baur, S., Hauser, A.K., Synofzik, M., Srulijes, K., Brockmann, K., Berg, D., and Maetzler, W. (2012). Cerebrospinal fluid fatty acids in glucocerebrosidase-associated Parkinson's disease. Mov Disord 27, 288-292.

Srulijes, K., Reimold, M., Liscic, R.M., Bauer, S., Dietzel, E., Liepelt-Scarfone, I., Berg, D., and Maetzler, W. (2012). Fluorodeoxyglucose positron emission tomography in Richardson's syndrome and progressive supranuclear palsy-parkinsonism. Mov Disord 27, 151-155.

Synofzik, M., Srulijes, K., Godau, J., Berg, D., and Schols, L. (2012). Characterizing POLG ataxia: clinics, electrophysiology and imaging. Cerebellum 11, 1002-1011.

Wachter, B., Schurger, S., Schmid, A., Groger, A., Sadler, R., Speidel, A., Rolinger, J., Pichler, B.J., Berg, D., Wagner, H.J., Von Ameln-Mayerhofer, A., and Kuppers, E. (2012). 6-Hydroxydopamine leads to T2 hyperintensity, decreased claudin-3 immunoreactivity and altered aquaporin 4 expression in the striatum. Behav Brain Res 232, 148-158.

Wang, Y., Shi, M., Chung, K.A., Zabetian, C.P., Leverenz, J.B., Berg, D., Srulijes, K., Trojanowski, J.Q., Lee, V.M., Siderowf, A.D., Hurtig, H., Litvan, I., Schiess, M.C., Peskind, E.R., Masuda, M., Hasegawa, M., Lin, X., Pan, C., Galasko, D., Goldstein, D.S., Jensen, P.H., Yang, H., Cain, K.C., and Zhang, J. (2012). Phosphorylated alpha-synuclein in Parkinson's disease. Sci Transl Med 4, 121ra120.

Weiss, D., Brockmann, K., Srulijes, K., Meisner, C., Klotz, R., Reinbold, S., Hauser, A.K., Schulte, C., Berg, D., Gasser, T., Plewnia, C., Gharabaghi, A., Breit, S., Wachter, T., and Kruger, R. (2012). Long-term follow-up of subthalamic nucleus stimulation in glucocerebrosidase-associated Parkinson's disease. J Neurol 259, 1970-1972. 

2011

 

Balzer-Geldsetzer, M., Costa, A.S., Kronenburger, M., Schulz, J.B., Roske, S., Spottke, A., Wullner, U., Klockgether, T., Storch, A., Schneider, C., Riedel, O., Wittchen, H.U., Seifried, C., Hilker, R., Schmidt, N., Witt, K., Deuschl, G., Mollenhauer, B., Trenkwalder, C., Liepelt-Scarfone, I., Graber-Sultan, S., Berg, D., Gasser, T., Kalbe, E., Bodden, M., Oertel, W.H., and Dodel, R. (2011). Parkinson's disease and dementia: a longitudinal study (DEMPARK). Neuroepidemiology 37, 168-176.

Berg, D. (2011a). Hyperechogenicity of the substantia nigra: pitfalls in assessment and specificity for Parkinson's disease. J Neural Transm 118, 453-461.

Berg, D. (2011b). Substantia nigra hyperechogenicity is a risk marker of Parkinson's disease: yes. J Neural Transm 118, 613-619.

Berg, D. (2011c). Tracking of striatal degeneration in prediagnostic Parkinson's disease: first steps into a promising future. Lancet Neurol 10, 775-776.

Berg, D., Godau, J., Trenkwalder, C., Eggert, K., Csoti, I., Storch, A., Huber, H., Morelli-Canelo, M., Stamelou, M., Ries, V., Wolz, M., Schneider, C., Di Paolo, T., Gasparini, F., Hariry, S., Vandemeulebroecke, M., Abi-Saab, W., Cooke, K., Johns, D., and Gomez-Mancilla, B. (2011a). AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials. Mov Disord 26, 1243-1250.

Berg, D., Seppi, K., Behnke, S., Liepelt, I., Schweitzer, K., Stockner, H., Wollenweber, F., Gaenslen, A., Mahlknecht, P., Spiegel, J., Godau, J., Huber, H., Srulijes, K., Kiechl, S., Bentele, M., Gasperi, A., Schubert, T., Hiry, T., Probst, M., Schneider, V., Klenk, J., Sawires, M., Willeit, J., Maetzler, W., Fassbender, K., Gasser, T., and Poewe, W. (2011b). Enlarged substantia nigra hyperechogenicity and risk for Parkinson disease: a 37-month 3-center study of 1847 older persons. Arch Neurol 68, 932-937.

Berg, D., Steinberger, J.D., Warren Olanow, C., Naidich, T.P., and Yousry, T.A. (2011c). Milestones in magnetic resonance imaging and transcranial sonography of movement disorders. Mov Disord 26, 979-992.

Berg, D.A., Kirkham, M., Wang, H., Frisen, J., and Simon, A. (2011d). Dopamine controls neurogenesis in the adult salamander midbrain in homeostasis and during regeneration of dopamine neurons. Cell Stem Cell 8, 426-433.

Bouman, L., Schlierf, A., Lutz, A.K., Shan, J., Deinlein, A., Kast, J., Galehdar, Z., Palmisano, V., Patenge, N., Berg, D., Gasser, T., Augustin, R., Trumbach, D., Irrcher, I., Park, D.S., Wurst, W., Kilberg, M.S., Tatzelt, J., and Winklhofer, K.F. (2011). Parkin is transcriptionally regulated by ATF4: evidence for an interconnection between mitochondrial stress and ER stress. Cell Death Differ 18, 769-782.

Brockmann, K., Groger, A., Di Santo, A., Liepelt, I., Schulte, C., Klose, U., Maetzler, W., Hauser, A.K., Hilker, R., Gomez-Mancilla, B., Berg, D., and Gasser, T. (2011a). Clinical and brain imaging characteristics in leucine-rich repeat kinase 2-associated PD and asymptomatic mutation carriers. Mov Disord 26, 2335-2342.

Brockmann, K., Srulijes, K., Hauser, A.K., Schulte, C., Csoti, I., Gasser, T., and Berg, D. (2011b). GBA-associated PD presents with nonmotor characteristics. Neurology 77, 276-280.

Fernandes Rde, C., Rosso, A.L., Vincent, M.B., Silva, K.S., Bonan, C., Araujo, N.C., and Berg, D. (2011). Transcranial sonography as a diagnostic tool for Parkinson's disease: a pilot study in the city of Rio de Janeiro, Brazil. Arq Neuropsiquiatr 69, 892-895.

Fernandez-Santiago, R., Sharma, M., Berg, D., Illig, T., Anneser, J., Meyer, T., Ludolph, A., and Gasser, T. (2011). No evidence of association of FLJ10986 and ITPR2 with ALS in a large German cohort. Neurobiol Aging 32, 551 e551-554.

Fritz, B., Rombach, S., Godau, J., Berg, D., Horstmann, T., and Grau, S. (2011). The influence of Nordic Walking training on sit-to-stand transfer in Parkinson patients. Gait Posture 34, 234-238.

Gaenslen, A., Swid, I., Liepelt-Scarfone, I., Godau, J., and Berg, D. (2011). The patients' perception of prodromal symptoms before the initial diagnosis of Parkinson's disease. Mov Disord 26, 653-658.

Godau, J., and Berg, D. (2011). Rotigotine in the Long-Term Treatment of Severe RLS with Augmentation: A Series of 28 Cases. Sleep Disord 2011, 468952.

Godau, J., Knauel, K., Weber, K., Brockmann, K., Maetzler, W., Binder, G., and Berg, D. (2011). Serum insulinlike growth factor 1 as possible marker for risk and early diagnosis of Parkinson disease. Arch Neurol 68, 925-931.

Graber, S., Liepelt-Scarfone, I., Brussel, T., Schweitzer, K., Gasser, T., and Berg, D. (2011). Self estimated quality of life in monogenetic Parkinson's disease. Mov Disord 26, 187-188.

Groger, A., Chadzynski, G., Godau, J., Berg, D., and Klose, U. (2011). Three-dimensional magnetic resonance spectroscopic imaging in the substantia nigra of healthy controls and patients with Parkinson's disease. Eur Radiol 21, 1962-1969.

Guthoff, M., Tschritter, O., Berg, D., Liepelt, I., Schulte, C., Machicao, F., Breer, H., Haering, H.U., and Fritsche, A. (2011). A polymorphism in the gene encoding AdipoR1 affects olfactory recognition. Int J Obes (Lond) 35, 873-876.

Hobert, M.A., Niebler, R., Meyer, S.I., Brockmann, K., Becker, C., Huber, H., Gaenslen, A., Godau, J., Eschweiler, G.W., Berg, D., and Maetzler, W. (2011). Poor trail making test performance is directly associated with altered dual task prioritization in the elderly--baseline results from the TREND study. PLoS One 6, e27831.

Laske, C., Fallgatter, A.J., Stransky, E., Hagen, K., Berg, D., and Maetzler, W. (2011). Decreased alpha-synuclein serum levels in patients with Lewy body dementia compared to Alzheimer's disease patients and control subjects. Dement Geriatr Cogn Disord 31, 413-416.

Liepelt-Scarfone, I., Behnke, S., Godau, J., Schweitzer, K.J., Wolf, B., Gaenslen, A., and Berg, D. (2011a). Relation of risk factors and putative premotor markers for Parkinson's disease. J Neural Transm 118, 579-585.

Liepelt-Scarfone, I., Graeber, S., Feseker, A., Baysal, G., Godau, J., Gaenslen, A., Maetzler, W., and Berg, D. (2011b). Influence of different cut-off values on the diagnosis of mild cognitive impairment in Parkinson's disease. Parkinsons Dis 2011, 540843.

Liepelt, I., Behnke, S., Schweitzer, K., Wolf, B., Godau, J., Wollenweber, F., Dillmann, U., Gaenslen, A., Di Santo, A., Maetzler, W., and Berg, D. (2011). Pre-motor signs of PD are related to SN hyperechogenicity assessed by TCS in an elderly population. Neurobiol Aging 32, 1599-1606.

Maetzler, W., Berg, D., Synofzik, M., Brockmann, K., Godau, J., Melms, A., Gasser, T., Hornig, S., and Langkamp, M. (2011a). Autoantibodies against amyloid and glial-derived antigens are increased in serum and cerebrospinal fluid of Lewy body-associated dementias. J Alzheimers Dis 26, 171-179.

Maetzler, W., Schmid, S.P., Wurster, I., Liepelt, I., Gaenslen, A., Gasser, T., and Berg, D. (2011b). Reduced but not oxidized cerebrospinal fluid glutathione levels are lowered in Lewy body diseases. Mov Disord 26, 176-181.

Maetzler, W., Stapf, A.K., Schulte, C., Hauser, A.K., Lerche, S., Wurster, I., Schleicher, E., Melms, A., and Berg, D. (2011c). Serum and cerebrospinal fluid uric acid levels in lewy body disorders: associations with disease occurrence and amyloid-beta pathway. J Alzheimers Dis 27, 119-126.

Roder, C., Peters, V., Kasuya, H., Nishizawa, T., Takehara, Y., Berg, D., Schulte, C., Khan, N., Tatagiba, M., and Krischek, B. (2011a). Common genetic polymorphisms in moyamoya and atherosclerotic disease in Europeans. Childs Nerv Syst 27, 245-252.

Roder, C., Peters, V., Kasuya, H., Nishizawa, T., Wakita, S., Berg, D., Schulte, C., Khan, N., Tatagiba, M., and Krischek, B. (2011b). Analysis of ACTA2 in European Moyamoya disease patients. Eur J Paediatr Neurol 15, 117-122.

Srulijes, K., Mallien, G., Bauer, S., Dietzel, E., Groger, A., Ebersbach, G., Berg, D., and Maetzler, W. (2011). In vivo comparison of Richardson's syndrome and progressive supranuclear palsy-parkinsonism. J Neural Transm 118, 1191-1197.

Synofzik, M., Godau, J., Lindig, T., Schols, L., and Berg, D. (2011a). Restless legs and substantia nigra hypoechogenicity are common features in Friedreich's ataxia. Cerebellum 10, 9-13.

Synofzik, M., Godau, J., Lindig, T., Schols, L., and Berg, D. (2011b). Transcranial sonography reveals cerebellar, nigral, and forebrain abnormalities in Friedreich's ataxia. Neurodegener Dis 8, 470-475.

Van Es, M.A., Schelhaas, H.J., Van Vught, P.W., Ticozzi, N., Andersen, P.M., Groen, E.J., Schulte, C., Blauw, H.M., Koppers, M., Diekstra, F.P., Fumoto, K., Leclerc, A.L., Keagle, P., Bloem, B.R., Scheffer, H., Van Nuenen, B.F., Van Blitterswijk, M., Van Rheenen, W., Wills, A.M., Lowe, P.P., Hu, G.F., Yu, W., Kishikawa, H., Wu, D., Folkerth, R.D., Mariani, C., Goldwurm, S., Pezzoli, G., Van Damme, P., Lemmens, R., Dahlberg, C., Birve, A., Fernandez-Santiago, R., Waibel, S., Klein, C., Weber, M., Van Der Kooi, A.J., De Visser, M., Verbaan, D., Van Hilten, J.J., Heutink, P., Hennekam, E.A., Cuppen, E., Berg, D., Brown, R.H., Jr., Silani, V., Gasser, T., Ludolph, A.C., Robberecht, W., Ophoff, R.A., Veldink, J.H., Pasterkamp, R.J., De Bakker, P.I., Landers, J.E., Van De Warrenburg, B.P., and Van Den Berg, L.H. (2011). Angiogenin variants in Parkinson disease and amyotrophic lateral sclerosis. Ann Neurol 70, 964-973.

2010

 

Behnke, S., Schroder, U., and Berg, D. (2010). Transcranial sonography in the premotor diagnosis of Parkinson's disease. Int Rev Neurobiol 90, 93-106.

Berg, D. (2010). Transcranial sonography in movement disorders. Conclusions. Int Rev Neurobiol 90, 287-289.

Berg, D., and Gaenslen, A. (2010). Place value of transcranial sonography in early diagnosis of Parkinson's disease. Neurodegener Dis 7, 291-299.

Berg, D., Godau, J., Riederer, P., Gerlach, M., and Arzberger, T. (2010a). Microglia activation is related to substantia nigra echogenicity. J Neural Transm 117, 1287-1292.

Berg, D., Seppi, K., Liepelt, I., Schweitzer, K., Wollenweber, F., Wolf, B., Dillmann, U., Stockner, H., Godau, J., Kiechl, S., Gaenslen, A., Willeit, J., Di Santo, A., Maetzler, W., Gasser, T., Poewe, W., and Behnke, S. (2010b). Enlarged hyperechogenic substantia nigra is related to motor performance and olfaction in the elderly. Mov Disord 25, 1464-1469.

Berg, D., and Walter, U. (2010). Preface. Summary of content--TCS in the diagnosis of movement disorders. Int Rev Neurobiol 90, xiii.

Friedrich, C., Rudiger, H., Schmidt, C., Herting, B., Prieur, S., Junghanns, S., Schweitzer, K., Globas, C., Schols, L., Berg, D., Reichmann, H., and Ziemssen, T. (2010). Baroreflex sensitivity and power spectral analysis during autonomic testing in different extrapyramidal syndromes. Mov Disord 25, 315-324.

Gaenslen, A., and Berg, D. (2010). Early diagnosis of Parkinson's disease. Int Rev Neurobiol 90, 81-92.

Godau, J., and Berg, D. (2010). Role of transcranial ultrasound in the diagnosis of movement disorders. Neuroimaging Clin N Am 20, 87-101.

Godau, J., Herfurth, M., Kattner, B., Gasser, T., and Berg, D. (2010a). Increased serum insulin-like growth factor 1 in early idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 81, 536-538.

Godau, J., Spinnler, N., Wevers, A.K., Trenkwalder, C., and Berg, D. (2010b). Poor effect of guideline based treatment of restless legs syndrome in clinical practice. J Neurol Neurosurg Psychiatry 81, 1390-1395.

Klebe, S., Thier, S., Lorenz, D., Nothnagel, M., Schreiber, S., Klein, C., Hagenah, J., Kasten, M., Berg, D., Srulijes, K., Gasser, T., Deuschl, G., and Kuhlenbaumer, G. (2010). LINGO1 is not associated with Parkinson's disease in German patients. Am J Med Genet B Neuropsychiatr Genet 153B, 1173-1178.

Liepelt, I., Gaenslen, A., Godau, J., Di Santo, A., Schweitzer, K.J., Gasser, T., and Berg, D. (2010). Rivastigmine for the treatment of dementia in patients with progressive supranuclear palsy: Clinical observations as a basis for power calculations and safety analysis. Alzheimers Dement 6, 70-74.

Lucking, C.B., Lichtner, P., Kramer, E.R., Gieger, C., Illig, T., Dichgans, M., Berg, D., and Gasser, T. (2010). Polymorphisms in the receptor for GDNF (RET) are not associated with Parkinson's disease in Southern Germany. Neurobiol Aging 31, 167-168.

Maetzler, W., Berg, D., Funke, C., Sandmann, F., Stunitz, H., Maetzler, C., and Nitsch, C. (2010a). Progressive secondary neurodegeneration and microcalcification co-occur in osteopontin-deficient mice. Am J Pathol 177, 829-839.

Maetzler, W., Schmid, B., Synofzik, M., Schulte, C., Riester, K., Huber, H., Brockmann, K., Gasser, T., Berg, D., and Melms, A. (2010b). The CST3 BB genotype and low cystatin C cerebrospinal fluid levels are associated with dementia in Lewy body disease. J Alzheimers Dis 19, 937-942.

Maetzler, W., Stoycheva, V., Schmid, B., Schulte, C., Hauser, A.K., Brockmann, K., Melms, A., Gasser, T., and Berg, D. (2010c). Neprilysin activity in cerebrospinal fluid is associated with dementia and amyloid-beta42 levels in Lewy body disease. J Alzheimers Dis 22, 933-938.

Manz, C., Godau, J., Berg, D., Bender, B., Ernemann, U., and Klose, U. (2010). The regional distribution of T2-relaxation times in MR images of the substantia nigra and crus cerebri. Neuroradiology 52, 745-750.

Nicolai, S., Mirelman, A., Herman, T., Zijlstra, A., Mancini, M., Becker, C., Lindemann, U., Berg, D., and Maetzler, W. (2010). Improvement of balance after audio-biofeedback. A 6-week intervention study in patients with progressive supranuclear palsy. Z Gerontol Geriatr 43, 224-228.

Pietzarka, K., Reimann, M., Schmidt, C., Herting, B., Schols, L., Reichmann, H., Berg, D., Schrader, C., and Ziemssen, T. (2010). The cold hand sign in multiple system atrophy: skin perfusion revisited. J Neural Transm 117, 475-479.

Reimann, M., Schmidt, C., Herting, B., Prieur, S., Junghanns, S., Schweitzer, K., Globas, C., Schoels, L., Reichmann, H., Berg, D., and Ziemssen, T. (2010). Comprehensive autonomic assessment does not differentiate between Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. J Neural Transm 117, 69-76.

Roder, C., Peters, V., Kasuya, H., Nishizawa, T., Takehara, Y., Berg, D., Schulte, C., Khan, N., Tatagiba, M., and Krischek, B. (2010). Polymorphisms in TGFB1 and PDGFRB are associated with Moyamoya disease in European patients. Acta Neurochir (Wien) 152, 2153-2160.

Soehn, A.S., Franck, T., Biskup, S., Giaime, E., Melle, C., Rott, R., Cebo, D., Kalbacher, H., Ott, E., Pahnke, J., Meitinger, T., Kruger, R., Gasser, T., Berg, D., Von Eggeling, F., Engelender, S., Da Costa, C.A., and Riess, O. (2010). Periphilin is a novel interactor of synphilin-1, a protein implicated in Parkinson's disease. Neurogenetics 11, 203-215.

Subramanian, T., Lieu, C.A., Guttalu, K., and Berg, D. (2010). Detection of MPTP-induced substantia nigra hyperechogenicity in Rhesus monkeys by transcranial ultrasound. Ultrasound Med Biol 36, 604-609.

Todd, G., Taylor, J.L., Baumann, D., Butler, J.E., Duma, S.R., Hayes, M., Carew-Jones, F., Piguet, O., Behnke, S., Ridding, M.C., Berg, D., and Double, K.L. (2010). Substantia nigra echomorphology and motor cortex excitability. Neuroimage 50, 1351-1356.

Van De Loo, S., Walter, U., Behnke, S., Hagenah, J., Lorenz, M., Sitzer, M., Hilker, R., and Berg, D. (2010). Reproducibility and diagnostic accuracy of substantia nigra sonography for the diagnosis of Parkinson's disease. J Neurol Neurosurg Psychiatry 81, 1087-1092.

Wachter, B., Schurger, S., Rolinger, J., Von Ameln-Mayerhofer, A., Berg, D., Wagner, H.J., and Kueppers, E. (2010). Effect of 6-hydroxydopamine (6-OHDA) on proliferation of glial cells in the rat cortex and striatum: evidence for de-differentiation of resident astrocytes. Cell Tissue Res 342, 147-160.

Walter, U., Skoloudik, D., and Berg, D. (2010). Transcranial sonography findings related to non-motor features of Parkinson's disease. J Neurol Sci 289, 123-127.

Woitalla, D., Braak, H., Tredici, K.D., Fogel, W., Hagenah, J., Oertel, W., and Berg, D. (2010). [Transcraniel ultrasound in the differential diagnosis of Parkinson's disease]. Fortschr Neurol Psychiatr 78 Suppl 1, S25-30.

2009

 

Behnke, S., Schroeder, U., Dillmann, U., Buchholz, H.G., Schreckenberger, M., Fuss, G., Reith, W., Berg, D., and Krick, C.M. (2009). Hyperechogenicity of the substantia nigra in healthy controls is related to MRI changes and to neuronal loss as determined by F-Dopa PET. Neuroimage 47, 1237-1243.

Berg, D. (2009). Transcranial ultrasound as a risk marker for Parkinson's disease. Mov Disord 24 Suppl 2, S677-683.

Djarmati, A., Hagenah, J., Reetz, K., Winkler, S., Behrens, M.I., Pawlack, H., Lohmann, K., Ramirez, A., Tadic, V., Bruggemann, N., Berg, D., Siebner, H.R., Lang, A.E., Pramstaller, P.P., Binkofski, F., Kostic, V.S., Volkmann, J., Gasser, T., and Klein, C. (2009). ATP13A2 variants in early-onset Parkinson's disease patients and controls. Mov Disord 24, 2104-2111.

Fernandez-Santiago, R., Hoenig, S., Lichtner, P., Sperfeld, A.D., Sharma, M., Berg, D., Weichenrieder, O., Illig, T., Eger, K., Meyer, T., Anneser, J., Munch, C., Zierz, S., Gasser, T., and Ludolph, A. (2009). Identification of novel Angiogenin (ANG) gene missense variants in German patients with amyotrophic lateral sclerosis. J Neurol 256, 1337-1342.

Fuchs, J., Mueller, J.C., Lichtner, P., Schulte, C., Munz, M., Berg, D., Wullner, U., Illig, T., Sharma, M., and Gasser, T. (2009). The transcription factor PITX3 is associated with sporadic Parkinson's disease. Neurobiol Aging 30, 731-738.

Funke, C., Soehn, A.S., Tomiuk, J., Riess, O., and Berg, D. (2009a). Genetic analysis of coding SNPs in blood-brain barrier transporter MDR1 in European Parkinson's disease patients. J Neural Transm 116, 443-450.

Funke, C., Tomiuk, J., Riess, O., Berg, D., and Soehn, A.S. (2009b). Genetic analysis of heme oxygenase-1 (HO-1) in German Parkinson's disease patients. J Neural Transm 116, 853-859.

Godau, J., Manz, A., Wevers, A.K., Gaenslen, A., and Berg, D. (2009). Sonographic substantia nigra hypoechogenicity in polyneuropathy and restless legs syndrome. Mov Disord 24, 133-137.

Golub, Y., Berg, D., Calne, D.B., Pfeiffer, R.F., Uitti, R.J., Stoessl, A.J., Wszolek, Z.K., Farrer, M.J., Mueller, J.C., Gasser, T., and Fuchs, J. (2009). Genetic factors influencing age at onset in LRRK2-linked Parkinson disease. Parkinsonism Relat Disord 15, 539-541.

Guthoff, M., Tschritter, O., Berg, D., Liepelt, I., Schulte, C., Machicao, F., Haering, H.U., and Fritsche, A. (2009). Effect of genetic variation in Kv1.3 on olfactory function. Diabetes Metab Res Rev 25, 523-527.

Liepelt, I., Reimold, M., Maetzler, W., Godau, J., Reischl, G., Gaenslen, A., Herbst, H., and Berg, D. (2009). Cortical hypometabolism assessed by a metabolic ratio in Parkinson's disease primarily reflects cognitive deterioration-[18F]FDG-PET. Mov Disord 24, 1504-1511.

Maetzler, W., Keller, S., Michelis, J., Koehler, N., Stransky, E., Becker, C., Schulte, C., Melms, A., Gasser, T., and Berg, D. (2009a). No differences of butyrylcholinesterase protein activity and allele frequency in Lewy body diseases. Neurobiol Dis 35, 296-301.

Maetzler, W., Liepelt, I., and Berg, D. (2009b). Progression of Parkinson's disease in the clinical phase: potential markers. Lancet Neurol 8, 1158-1171.

Maetzler, W., Liepelt, I., Reimold, M., Reischl, G., Solbach, C., Becker, C., Schulte, C., Leyhe, T., Keller, S., Melms, A., Gasser, T., and Berg, D. (2009c). Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. Neurobiol Dis 34, 107-112.

Maetzler, W., Michelis, J., Tomiuk, J., Melms, A., Becker, C., Gasser, T., Schulte, C., and Berg, D. (2009d). A single-nucleotide polymorphism of the osteopontin gene may contribute to a susceptibility to Lewy body disease. J Neural Transm 116, 599-605.

Rothfuss, O., Fischer, H., Hasegawa, T., Maisel, M., Leitner, P., Miesel, F., Sharma, M., Bornemann, A., Berg, D., Gasser, T., and Patenge, N. (2009). Parkin protects mitochondrial genome integrity and supports mitochondrial DNA repair. Hum Mol Genet 18, 3832-3850.

Schmidt, C., Berg, D., Herting, Prieur, S., Junghanns, S., Schweitzer, K., Globas, C., Schols, L., Reichmann, H., and Ziemssen, T. (2009a). Loss of nocturnal blood pressure fall in various extrapyramidal syndromes. Mov Disord 24, 2136-2142.

Schmidt, C., Herting, B., Prieur, S., Junghanns, S., Schweitzer, K., Globas, C., Schols, L., Reichmann, H., Berg, D., and Ziemssen, T. (2009b). Valsalva manoeuvre in patients with different Parkinsonian disorders. J Neural Transm 116, 875-880.

Scholz, S.W., Houlden, H., Schulte, C., Sharma, M., Li, A., Berg, D., Melchers, A., Paudel, R., Gibbs, J.R., Simon-Sanchez, J., Paisan-Ruiz, C., Bras, J., Ding, J., Chen, H., Traynor, B.J., Arepalli, S., Zonozi, R.R., Revesz, T., Holton, J., Wood, N., Lees, A., Oertel, W., Wullner, U., Goldwurm, S., Pellecchia, M.T., Illig, T., Riess, O., Fernandez, H.H., Rodriguez, R.L., Okun, M.S., Poewe, W., Wenning, G.K., Hardy, J.A., Singleton, A.B., Del Sorbo, F., Schneider, S., Bhatia, K.P., and Gasser, T. (2009). SNCA variants are associated with increased risk for multiple system atrophy. Ann Neurol 65, 610-614.

Sharma, M., Lichtner, P., Kruger, R., Berg, D., Schulte, C., Illig, T., Riess, O., and Gasser, T. (2009). Further delineation of the association signal on chromosome 5 from the first whole genome association study in Parkinson's disease. Neurobiol Aging 30, 1706-1709.

Sidransky, E., Nalls, M.A., Aasly, J.O., Aharon-Peretz, J., Annesi, G., Barbosa, E.R., Bar-Shira, A., Berg, D., Bras, J., Brice, A., Chen, C.M., Clark, L.N., Condroyer, C., De Marco, E.V., Durr, A., Eblan, M.J., Fahn, S., Farrer, M.J., Fung, H.C., Gan-Or, Z., Gasser, T., Gershoni-Baruch, R., Giladi, N., Griffith, A., Gurevich, T., Januario, C., Kropp, P., Lang, A.E., Lee-Chen, G.J., Lesage, S., Marder, K., Mata, I.F., Mirelman, A., Mitsui, J., Mizuta, I., Nicoletti, G., Oliveira, C., Ottman, R., Orr-Urtreger, A., Pereira, L.V., Quattrone, A., Rogaeva, E., Rolfs, A., Rosenbaum, H., Rozenberg, R., Samii, A., Samaddar, T., Schulte, C., Sharma, M., Singleton, A., Spitz, M., Tan, E.K., Tayebi, N., Toda, T., Troiano, A.R., Tsuji, S., Wittstock, M., Wolfsberg, T.G., Wu, Y.R., Zabetian, C.P., Zhao, Y., and Ziegler, S.G. (2009). Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med 361, 1651-1661.

Simon-Sanchez, J., Schulte, C., Bras, J.M., Sharma, M., Gibbs, J.R., Berg, D., Paisan-Ruiz, C., Lichtner, P., Scholz, S.W., Hernandez, D.G., Kruger, R., Federoff, M., Klein, C., Goate, A., Perlmutter, J., Bonin, M., Nalls, M.A., Illig, T., Gieger, C., Houlden, H., Steffens, M., Okun, M.S., Racette, B.A., Cookson, M.R., Foote, K.D., Fernandez, H.H., Traynor, B.J., Schreiber, S., Arepalli, S., Zonozi, R., Gwinn, K., Van Der Brug, M., Lopez, G., Chanock, S.J., Schatzkin, A., Park, Y., Hollenbeck, A., Gao, J., Huang, X., Wood, N.W., Lorenz, D., Deuschl, G., Chen, H., Riess, O., Hardy, J.A., Singleton, A.B., and Gasser, T. (2009). Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet 41, 1308-1312.

Simon, A., Berg, D., and Kirkham, M. (2009). Not lost in translation Sensing the loss and filling the gap during regeneration. Semin Cell Dev Biol 20, 691-696.

2008

 

Berg, D. (2008). Biomarkers for the early detection of Parkinson's and Alzheimer's disease. Neurodegener Dis 5, 133-136.

Berg, D., Godau, J., and Walter, U. (2008). Transcranial sonography in movement disorders. Lancet Neurol 7, 1044-1055.

Friedrich, C., Rudiger, H., Schmidt, C., Herting, B., Prieur, S., Junghanns, S., Schweitzer, K., Globas, C., Schols, L., Berg, D., Reichmann, H., and Ziemssen, T. (2008). Baroreflex sensitivity and power spectral analysis in different extrapyramidal syndromes. J Neural Transm 115, 1527-1536.

Fuchs, J., Tichopad, A., Golub, Y., Munz, M., Schweitzer, K.J., Wolf, B., Berg, D., Mueller, J.C., and Gasser, T. (2008). Genetic variability in the SNCA gene influences alpha-synuclein levels in the blood and brain. FASEB J 22, 1327-1334.

Gaenslen, A., Gasser, T., and Berg, D. (2008a). Nutrition and the risk for Parkinson's disease: review of the literature. J Neural Transm 115, 703-713.

Gaenslen, A., Unmuth, B., Godau, J., Liepelt, I., Di Santo, A., Schweitzer, K.J., Gasser, T., Machulla, H.J., Reimold, M., Marek, K., and Berg, D. (2008b). The specificity and sensitivity of transcranial ultrasound in the differential diagnosis of Parkinson's disease: a prospective blinded study. Lancet Neurol 7, 417-424.

Godau, J., Klose, U., Di Santo, A., Schweitzer, K., and Berg, D. (2008a). Multiregional brain iron deficiency in restless legs syndrome. Mov Disord 23, 1184-1187.

Godau, J., Wevers, A.K., Gaenslen, A., Di Santo, A., Liepelt, I., Gasser, T., and Berg, D. (2008b). Sonographic abnormalities of brainstem structures in restless legs syndrome. Sleep Med 9, 782-789.

Haugarvoll, K., Rademakers, R., Kachergus, J.M., Nuytemans, K., Ross, O.A., Gibson, J.M., Tan, E.K., Gaig, C., Tolosa, E., Goldwurm, S., Guidi, M., Riboldazzi, G., Brown, L., Walter, U., Benecke, R., Berg, D., Gasser, T., Theuns, J., Pals, P., Cras, P., De Deyn, P.P., Engelborghs, S., Pickut, B., Uitti, R.J., Foroud, T., Nichols, W.C., Hagenah, J., Klein, C., Samii, A., Zabetian, C.P., Bonifati, V., Van Broeckhoven, C., Farrer, M.J., and Wszolek, Z.K. (2008). Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease. Neurology 70, 1456-1460.

Kamm, C., Fogel, W., Wachter, T., Schweitzer, K., Berg, D., Kruger, R., Freudenstein, D., and Gasser, T. (2008). Novel ATP1A3 mutation in a sporadic RDP patient with minimal benefit from deep brain stimulation. Neurology 70, 1501-1503.

Liepelt, I., Maetzler, W., Blaicher, H.P., Gasser, T., and Berg, D. (2008a). [Treatment for dementia in parkinsonian syndromes. Efficacy of cholinesterase inhibitors]. Nervenarzt 79, 36-39, 42-36.

Liepelt, I., Wendt, A., Schweitzer, K.J., Wolf, B., Godau, J., Gaenslen, A., Bruessel, T., and Berg, D. (2008b). Substantia nigra hyperechogenicity assessed by transcranial sonography is related to neuropsychological impairment in the elderly population. J Neural Transm 115, 993-999.

Lucking, C.B., Lichtner, P., Dichgans, M., Illig, T., Gieger, C., Berg, D., and Gasser, T. (2008). Polymorphisms in the proteasomal subunit alpha4 are not associated with Parkinson's disease. J Neurol 255, 441-442.

Maetzler, W., Reimold, M., Liepelt, I., Solbach, C., Leyhe, T., Schweitzer, K., Eschweiler, G.W., Mittelbronn, M., Gaenslen, A., Uebele, M., Reischl, G., Gasser, T., Machulla, H.J., Bares, R., and Berg, D. (2008). [11C]PIB binding in Parkinson's disease dementia. Neuroimage 39, 1027-1033.

Prestel, J., Gempel, K., Hauser, T.K., Schweitzer, K., Prokisch, H., Ahting, U., Freudenstein, D., Bueltmann, E., Naegele, T., Berg, D., Klopstock, T., and Gasser, T. (2008). Clinical and molecular characterisation of a Parkinson family with a novel PINK1 mutation. J Neurol 255, 643-648.

Schmidt, C., Herting, B., Prieur, S., Junghanns, S., Schweitzer, K., Reichmann, H., Berg, D., and Ziemssen, T. (2008). Autonomic dysfunction in patients with progressive supranuclear palsy. Mov Disord 23, 2083-2089.

Schroeder, C., Walter, M., Berg, D., Leitner, P., Bauer, P., Kohl, Z., Winkler, J., Riess, O., and Bonin, M. (2008). High-throughput homogeneous mass cleave assay technology for the diagnosis of autosomal recessive Parkinson's disease. J Mol Diagn 10, 217-224.

Unger, M.M., Moller, J.C., Stiasny-Kolster, K., Mankel, K., Berg, D., Walter, U., Hoeffken, H., Mayer, G., and Oertel, W.H. (2008). Assessment of idiopathic rapid-eye-movement sleep behavior disorder by transcranial sonography, olfactory function test, and FP-CIT-SPECT. Mov Disord 23, 596-599.

Allgemeine Parkinson-Ambulanz 

 

Mehr als 1% der über 60-jährigen leidet an der Parkinson-Erkrankung, welche aber auch immer häufiger bei deutlich jüngeren Menschen diagnostiziert wird. Für eine differenzierte Therapie ist die Erstellung einer sicheren Diagnose vorrangig. Andere parkinson-ähnliche Krankheitsbilder müssen daher von der Parkinson-Krankheit im engeren Sinne abgegrenzt werden, um eine optimale individuelle Therapie zu ermöglichen. 

Die Spezialambulanz des Zentrums für Neurologie bietet die Voraussetzungen für optimale Diagnostik und optimierte individuelle Therapie dieser Erkrankungen.

Sprechstunden, Ansprechpartner und weitere Informationen auf finden Sie auf der Seite der Allgemeinen Parkinson-Ambulanz des Universitätsklinikums Tübingen. 

 

 

Forschungsgruppenleitung
Prof. Daniela Berg daniela.berg(at)uni-tuebingen.de Anschrift

Zentrum für Neurologie
Hertie-Institut für klinische Hirnforschung
Abteilung Neurologie mit Schwerpunkt neurodegenerative Erkrankungen

Hoppe-Seyler-Straße 3
72076 Tübingen

Fax: +49 (0)7071 29-4490